Manages spasticity. ANDA 212196, held by Alkem Laboratories. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 212196 (Tizanidine Hydrochloride), held by Alkem Laboratories, was first approved by FDA on Mar 27, 2019, with 2 approved supplements and 0 published complete response letters.
Tizanidine hydrochloride is indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride should be reserved for those daily activities and times when relief of spasticity is most important.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2019 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Sep 30, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 10, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 27, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters